ACHIEVEMENT OF LOW DISEASE ACTIVITY IN PATIENTS INITIATING INFLIXIMAB WITH AND WITHOUT DOSE ESCALATION

被引：0
作者：
Cohen, S. [1 ]
Reed, G. [2 ]
Magner, R. [3 ]
Kafka, S. [4 ]
Ellis, L. [4 ]
DeHoratius, R. J. [5 ]
Greenberg, J. D. [6 ]
机构：
[1] Metroplex Clin Res Ctr, Dallas, TX USA
[2] LLC Mass Med Sch, Corrona, Southborough, MA USA
[3] U Mass Med Sch, Worcester, MA USA
[4] Janssen Sci Affairs LLC, Horsham, PA USA
[5] Horsham Phila, LLC Kimmel Sch Med, Janssen Sci Affairs, Horsham, PA USA
[6] NYU, LLC, Sch Med, Corrona, Southborough, NY USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2016年 / 75卷
关键词：
D O I：
10.1136/annrheumdis-2016-eular.2771
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
THU0156
引用
收藏
页码：238 / 239
页数：2
相关论文
共 50 条
  • [21] Comparison of Dose Escalation and Co-therapy Intensification between Patients with Rheumatoid Arthritis Initiating Biologic Treatment with Etanercept, Adalimumab and Infliximab
    Thorne, Carter
    Boire, Gilles
    Chow, Andrew
    Garces, Kirsten
    Poulin-Costello, Melanie
    Walker, Valery
    Haraoui, Boulos
    JOURNAL OF RHEUMATOLOGY, 2016, 43 (06) : 1171 - 1171
  • [22] Prediction of dose escalation for rheumatoid arthritis patients under infliximab treatment
    Van Looy, Stijn
    Cruyssen, Bert Vander
    Meeus, Jeroen
    Wyns, Bart
    Westhovens, Rene
    Durez, Patrick
    Van den Bosch, Filip
    Vastesaeger, Nathan
    Geldhof, Anja
    Boullart, Luc
    De Keyser, Filip
    ENGINEERING APPLICATIONS OF ARTIFICIAL INTELLIGENCE, 2006, 19 (07) : 819 - 828
  • [23] WEEK 10 INFLIXIMAB CONCENTRATION IDENTIFIES PATIENTS THAT REQUIRE EARLY DOSE ESCALATION IN INFLAMMATORY BOWEL DISEASE
    Salem, Mark
    Ha, Christina
    Syal, Gaurav
    GASTROENTEROLOGY, 2019, 156 (03) : S38 - S39
  • [24] WEEK 10 INFLIXIMAB CONCENTRATION IDENTIFIES PATIENTS THAT REQUIRE EARLY DOSE ESCALATION IN INFLAMMATORY BOWEL DISEASE
    Salem, Mark
    Ha, Christina
    Syal, Gaurav
    INFLAMMATORY BOWEL DISEASES, 2019, 25 : S27 - S27
  • [25] Infliximab dose escalation in patients with rheumatoid arthritis: Results from the start trial
    Westhovens, R
    Wolfe, F
    Rahman, MU
    Han, J
    Yocum, D
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 423 - 423
  • [26] Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn's Disease Patients with Loss of Response to Adalimumab, Especially in Cases without Previous Infliximab Treatment
    Suzuki, Taketo
    Mizoshita, Tsutomu
    Sugiyama, Tomoya
    Hirata, Yoshikazu
    Kimura, Yoshihide
    Suzuki, Yuka
    Yamada, Tomonori
    Tsukamoto, Hironobu
    Mizushima, Takashi
    Sugimura, Naomi
    Katano, Takahito
    Tanida, Satoshi
    Kataoka, Hiromi
    Sasaki, Makoto
    CASE REPORTS IN GASTROENTEROLOGY, 2019, 13 (01) : 37 - 49
  • [27] RETROSPECTIVE STUDY OF DOSE ESCALATION WITH ADALIMUMAB, INFLIXIMAB, AND VEDOLIZUMAB IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
    Zhang, K. H.
    Singh, H.
    Twardowski, R.
    Lu, C.
    Wan, Y.
    Null, K.
    VALUE IN HEALTH, 2020, 23 : S143 - S143
  • [28] Long-term Durability of Infliximab Treatment in Crohn's Disease and Efficacy of Dose "Escalation" in Patients Losing Response
    Chaparro, Maria
    Panes, Julian
    Garcia, Valle
    Manosa, Miriam
    Esteve, Maria
    Merino, Olga
    Andreu, Montserrat
    Gutierrez, Ana
    Gomollon, Fernando
    Luis Cabriada, Jose
    Angel Montoro, Miguel
    Luis Mendoza, Juan
    Nos, Pilar
    Gisbert, Javier P.
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2011, 45 (02) : 113 - 118
  • [29] Retrospective Database Analysis: Dose Escalation and Adherence in Patients Initiating Biologics for Ulcerative Colitis
    Long, Millie D. D.
    Cohen, Russell D. D.
    Smith, Timothy W. W.
    DiBonaventura, Marco
    Gruben, David
    Bargo, Danielle
    Salese, Leonardo
    Quirk, Daniel
    DIGESTIVE DISEASES, 2021, : 553 - 564
  • [30] Infliximab dose escalation in patients with rheumatoid arthritis: Results from the START trial.
    Westhovens, R
    Wolfe, F
    Rahman, MU
    Han, J
    Yocum, D
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S185 - S186
12345